See more : Marie Brizard Wine & Spirits SA (BVDRF) Income Statement Analysis – Financial Results
Complete financial analysis of Catheter Precision, Inc. (VTAK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Catheter Precision, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Graphite Design Inc. (7847.T) Income Statement Analysis – Financial Results
- PTT Exploration and Production Public Company Limited (PTTEP-R.BK) Income Statement Analysis – Financial Results
- Silverstar Holdings Ltd. (SSTRF) Income Statement Analysis – Financial Results
- FirstRand Limited (FANDY) Income Statement Analysis – Financial Results
- SAP SE (SAP) Income Statement Analysis – Financial Results
Catheter Precision, Inc. (VTAK)
About Catheter Precision, Inc.
Catheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also provides LockeT, a suture retention device; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device. The company was formerly known as Ra Medical Systems, Inc and changed its name to Catheter Precision, Inc. in August 2023. Catheter Precision, Inc. is based in Fort Mill, South Carolina.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 442.00K | 14.00K | 22.00K | 4.41M | 7.20M | 6.26M | 5.87M | 5.98M |
| Cost of Revenue | 30.00K | 161.00K | 1.56M | 5.48M | 8.85M | 4.21M | 4.17M | 3.14M |
| Gross Profit | 412.00K | -147.00K | -1.54M | -1.08M | -1.65M | 2.05M | 1.71M | 2.84M |
| Gross Profit Ratio | 93.21% | -1,050.00% | -6,990.91% | -24.45% | -22.93% | 32.78% | 29.05% | 47.49% |
| Research & Development | 475.00K | 6.39M | 12.25M | 9.01M | 4.53M | 2.78M | 4.52M | 1.72M |
| General & Administrative | 0.00 | 2.23M | 0.00 | 25.97M | 51.55M | 30.44M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 1.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.12M | 16.25M | 15.48M | 25.97M | 51.55M | 30.44M | 14.95M | 5.32M |
| Other Expenses | 60.93M | 99.00K | 2.01M | 21.00K | 788.00K | 338.00K | 14.95M | 5.32M |
| Operating Expenses | 78.53M | 22.64M | 27.73M | 34.98M | 56.08M | 33.21M | 19.47M | 7.04M |
| Cost & Expenses | 78.56M | 22.80M | 29.29M | 40.46M | 64.93M | 37.42M | 23.63M | 10.17M |
| Interest Income | 347.00K | 0.00 | 0.00 | 129.00K | 1.04M | 352.00K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 3.08M | 0.00 | 108.00K | 250.00K | 14.00K | 4.00K | 3.00K |
| Depreciation & Amortization | 2.08M | 421.00K | 1.40M | 2.00M | 1.75M | 624.00K | 218.00K | 95.00K |
| EBITDA | -15.11M | -22.37M | -27.70M | -33.30M | -54.94M | -30.18M | -17.54M | -4.10M |
| EBITDA Ratio | -3,418.55% | -129,971.43% | -133,027.27% | -818.59% | -801.92% | -498.00% | -298.84% | -68.66% |
| Operating Income | -78.12M | -26.96M | -29.27M | -36.06M | -57.73M | -31.16M | -17.76M | -4.20M |
| Operating Income Ratio | -17,673.98% | -192,578.57% | -133,027.27% | -818.59% | -801.92% | -498.00% | -302.56% | -70.25% |
| Total Other Income/Expenses | 7.55M | -4.07M | 2.01M | 88.00K | 788.00K | 338.00K | -4.00K | -3.00K |
| Income Before Tax | -70.57M | -26.86M | -27.26M | -36.04M | -56.94M | -30.82M | -17.76M | -4.20M |
| Income Before Tax Ratio | -15,966.52% | -191,871.43% | -123,895.45% | -818.12% | -790.97% | -492.60% | -302.62% | -70.30% |
| Income Tax Expense | 0.00 | 3.00K | 4.00K | 7.00K | 15.00K | 10.00K | 1.00K | 1.00K |
| Net Income | -70.57M | -26.87M | -25.07M | -36.05M | -56.96M | -30.83M | -17.77M | -4.20M |
| Net Income Ratio | -15,966.52% | -191,892.86% | -113,954.55% | -818.27% | -791.18% | -492.76% | -302.64% | -70.31% |
| EPS | -12.99 | -25.98 | -248.22 | -1.06K | -5.42K | -4.18K | -1.83K | -433.96 |
| EPS Diluted | -12.99 | -25.98 | -248.22 | -1.06K | -5.42K | -4.18K | -1.83K | -433.96 |
| Weighted Avg Shares Out | 5.50M | 1.03M | 101.00K | 33.98K | 10.52K | 7.38K | 9.68K | 9.68K |
| Weighted Avg Shares Out (Dil) | 5.50M | 1.03M | 101.00K | 33.98K | 10.52K | 7.38K | 9.68K | 9.68K |
Catheter Precision's VIVO System Featured in Electrophysiology Publication
FORT MILL, SC / ACCESSWIRE / January 17, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a leader in non-invasive 3D mapping for ventricular arrhythmias, announced that their VIVO System was highlighted as part of a case study in...
CORRECTION: Catheter Precision, Inc.'s (VTAK) Board Authorizes its CEO and Chairman to Make "Open Market" Purchases of Company Shares
(This release corrects the release that was posted earlier on January 11, 2024 to update company information) FORT MILL, SC / ACCESSWIRE / January 11, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), an innovative US-based medical device Company...
Cather Precision, Inc.'s (VTAK) Board Authorizes its CEO and Chairman to Make "Open Market" Purchases of Company Shares
FORT MILL, SC / ACCESSWIRE / January 11, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), an innovative US-based medical device Company dedicated to improving the lives of patients with cardiac arrhythmias, announces that its CEO and Chairman, Mr....
CATHETER PRECISION, INC. (VTAK) Reports Unaudited Preliminary Fourth Quarter and Full Year 2023 Results
FORT MILL, SC / ACCESSWIRE / January 10, 2024 / Catheter Precision, Inc. (VTAK:NYSE/American) an innovative US-based medical device Company dedicated to improving the lives of patients with cardiac arrhythmias, announced corporate highlights and unaudited preliminary annual and fourth quarter...
Catheter Precision, Inc. (VTAK) Announces Changes to Executive Management and Board of Directors
FORT MILL, SC / ACCESSWIRE / January 3, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a US based innovative medical device company focused on electrophysiology products, today announced changes to the executive management and board of directors, including...
Catheter Precision, Inc. (VTAK) Receives Additional Patents for LockeT in Great Britain and the European Market
New Patents Demonstrate Uniqueness of the Closure Product Design FORT MILL, SC / ACCESSWIRE / January 2, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a US based innovative medical device company focused on electrophysiology products, announced today that...
Catheter Precision, Inc. Reports Third Quarter Results of Operations and Filing of Third Quarter 10-Q
FORT MILL, SC / ACCESSWIRE / December 22, 2023 / Catheter Precision, Inc. (NYSE American:VTAK) an innovative US-based medical device Company dedicated to improving the lives of patients with cardiac arrhythmias, announced corporate highlights of the third quarter of 2023....
CATHETER PRECISION, INC. Reports Filing of 10-Q and Second Quarter Results of Operations
FORT MILL, SC / ACCESSWIRE / December 18, 2023 / Catheter Precision, Inc. (formerly known as Ra Medical Systems, Inc.) (NYSE American:VTAK) an innovative US-based medical device Company dedicated to improving the lives of patients with cardiac arrhythmias, announced corporate...
Catheter Precision, Inc. (NYSE American:VTAK) Presenting at the Emerging Growth Conference on December 6, 2023
FORT MILL, SC / ACCESSWIRE / December 5, 2023 / Catheter Precision, Inc. (NYSE American:VTAK) is pleased to announce that it has been invited to present at the Emerging Growth Conference on December 6, 2023. Catheter Precision, Inc. (NYSE American:...
Catheter Precision's (VTAK) First Successful VIVO(TM) Cases Completed in Croatia Sets Stage for Expansion into South-Eastern Europe
FORT MILL, SC / ACCESSWIRE / November 20, 2023 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a pioneering medical technology firm headquartered in the United States, specializing in electrophysiology devices, has proudly disclosed the successful conclusion of the inaugural...
Source: https://incomestatements.info
Category: Stock Reports